Soft Tissue Sarcoma - Pipeline Insight, 2024

Soft Tissue Sarcoma - Pipeline Insight, 2024

DelveInsight’s, “Soft Tissue Sarcoma - Pipeline Insight, 2024,” report provides comprehensive insights about 125+ companies and 130+ pipeline drugs in Soft Tissue Sarcoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Soft Tissue Sarcoma Understanding

Soft Tissue Sarcoma: Overview

Soft tissue sarcoma is a disease in which malignant (cancer) cells form in the soft tissues of the body. Having certain inherited disorders can increase the risk of soft tissue sarcoma. A sign of soft tissue sarcoma is a lump or swelling in soft tissue of the body. Soft tissue sarcoma is diagnosed with a biopsy. Soft-tissue sarcomas are a group of cancers that begin in the connective tissues that support and connect the body, including: Blood vessels, Fat cells, Lining of joints, Lymph vessels, Muscle, Nerves and Tendons. As a result, soft-tissue sarcomas can occur almost anywhere in the body. When a soft-tissue sarcoma begins and is small, it can go unnoticed because it usually does not cause problems, such as pain. However, as a sarcoma grows, it can cause pain or interfere with the body's normal functions. Not all sarcomas are the same. Because there are more than 70 different types of soft-tissue sarcoma and each has a different natural history—meaning where they start, how they affect the body, how fast they grow, and how they respond to treatment—it is more accurate to describe them as a family of related diseases rather than as a single disease. Specific types of sarcoma are often named according to the normal tissue cells they most closely resemble. This is different from most other types of cancer, which usually are named for the part of the body where the cancer began. Some sarcomas do not look like any type of normal tissue, so they are named by what they look like under the microscope or according to their genetics rather than the tissues they are suspected to have started in. When a tumor is found and the doctor believes it could be sarcoma, it is important to find out the specific type of sarcoma as part of the diagnosis process. Because there are so many different types of sarcomas, it is best if an expert pathologist who specializes in sarcoma examines the tumor sample. The treatment options and prognosis depend on the following: The type of soft tissue sarcoma, the size, grade, and stage of the tumor, where the tumor is in the body, whether all of the tumor is removed by surgery, the patient's age and general health and whether the cancer has recurred (come back). Small, low-grade tumors, especially in the trunk, arms, or legs, are frequently treated with surgery alone. High-grade sarcomas are more difficult to treat and more likely to spread.

""Soft Tissue Sarcoma - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Soft Tissue Sarcoma pipeline landscape is provided which includes the disease overview and Soft Tissue Sarcoma treatment guidelines. The assessment part of the report embraces, in depth Soft Tissue Sarcoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Soft Tissue Sarcoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Soft Tissue Sarcoma R&D. The therapies under development are focused on novel approaches to treat/improve Soft Tissue Sarcoma.

Soft Tissue Sarcoma Emerging Drugs Chapters

This segment of the Soft Tissue Sarcoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Soft Tissue Sarcoma Emerging Drugs

• Anlotinib: Advenchen Laboratories, LLC

Anlotinib was developed by Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. as a new oral molecular RTK inhibitor; it targets VEGFR1, VEGFR3, VEGFR2/KDR, PDGFR-α, c-Kit, and FGFRs 1–3 and inhibits TA and tumor cell proliferation. Anlotinib may inhibit more targets than that do other RTK inhibitors, such as pazopanib, sunitinib, and sorafenib. The main mechanisms of action of anlotinib are as follows: preclinical studies have shown that anlotinib inhibits VEGF/PDGF-BB/FGF-2-induced cell migration, angiogenesis, and capillary-like tube formation in endothelial cells. More specifically, the mechanism involves the inhibition of the downstream ERK signaling pathway. Anlotinib has stronger anti-angiogenesis activity than that do other antiangiogenic agents (sunitinib and sorafenib). Currently, it is in Phase III stage of clinical trial evaluation to treat Soft Tissue Sarcoma.

• Fibromun: Philogen

Fibromun (L19TNF) is a fully-human immunomodulatory product consisting of the L19 antibody and TNF (a strong pro-inflammatory cytokine). (Recombinant TNF has so far been approved only for certain clinical applications). The fusion of TNF to the L19 antibody specific to the EDB domain of fibronectin results in a tumor-targeted product, which selectively localizes at the site of disease, while sparing healthy organs. Fibromun has shown potent anti-tumor activity, both as single agent and in combination with other drugs, in several immunocompetent preclinical models inducing in most cases long-lasting complete responses. Fibromun has previously been studied in clinical trials as monotherapy for systemic administration in patients with solid tumors and in melanoma patients using the Isolated Limb-Perfusion procedure. In preclinical models of sarcoma, Fibromun has, when combined with doxorubicin or dacarbazine (which are standard therapies for first line and third line sarcoma, respectively), cured all treated animals . Based on the encouraging results observed in the phase Ib study conducted in patients with metastatic Soft Tissue Sarcoma, three clinical trials with registration potential have started in Europe and in the United States. Currently the drug is in Phase III stage of Clinical trial evaluation for the treatment of Soft tissue sarcoma.

• Camsirubicin: Monopar Therapeutics

Camsirubicin is a novel proprietary analog of the widely used cancer drug doxorubicin. Camsirubicin has been engineered specifically to retain the anticancer activity of doxorubicin while minimizing the toxic effects on the heart. Preclinical and early clinical studies support the hypothesis that camsirubicin will be less cardiotoxic while retaining anti-cancer activity. Monopar believes the results of these studies, along with the potential to combine a less or non-cardiotoxic analog of doxorubicin with other anticancer agents, emphasizes a large market opportunity for camsirubicin in a broad spectrum of cancer types. The antitumor effects of camsirubicin are mediated through mechanisms common to all anthracyclines including doxorubicin. These mechanisms include the stabilization of the topoisomerase II complex after a DNA strand break and DNA intercalation leading to apoptosis (cell death). Inhibiting the topoisomerase IIα isoform achieves the anticancer effect, while inhibiting the topoisomerase IIβ isoform, which is expressed in cardiomyocytes but not in cancer cells, mediates, at least in part, the cardiotoxicity associated with all anthracycline drugs currently used in the clinic. In contrast to doxorubicin, camsirubicin exhibits some selectivity for inhibiting the topoisomerase IIα isoform over the topoisomerase IIβ isoform. This selectivity may explain the minimal cardiotoxicity that camsirubicin has demonstrated in clinical studies to date.

Further product details are provided in the report……..

Soft Tissue Sarcoma: Therapeutic Assessment

This segment of the report provides insights about the different Soft Tissue Sarcoma drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Soft Tissue Sarcoma

There are approx. 125+ key companies which are developing the therapies for Soft Tissue Sarcoma. The companies which have their Soft Tissue Sarcoma drug candidates in the most advanced stage, i.e. phase III include, Advenchen Laboratories, LLC.

• Phases

DelveInsight’s report covers around 130+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Soft Tissue Sarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Soft Tissue Sarcoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Soft Tissue Sarcoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Soft Tissue Sarcoma drugs.

Soft Tissue Sarcoma Report Insights

• Soft Tissue Sarcoma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Soft Tissue Sarcoma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Soft Tissue Sarcoma drugs?
• How many Soft Tissue Sarcoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Soft Tissue Sarcoma?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Soft Tissue Sarcoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Soft Tissue Sarcoma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Advenchen Laboratories
• Philogen
• Gradalis
• Epizyme
• Chugai Pharma France
• CytRx
• Taiho Pharmaceuticals
• KaryoPharm Therapeutics
• Nanobiotix
• Apexigen
• Lytix Biopharma
• Incyte Corporation
• Iovance Biotherapeutics
• Aadi Bioscience, Inc.
• AVEO Pharmaceuticals
• Bayer
• VasGene Therapeutics
• Mirati Therapeutics
• Novartis Pharmaceuticals
• Incyte Corporation
• Tracon Pharmaceuticals
• Jiangsu Hengrui Medicine
• Exelixis
• Qbiotics
• AstraZeneca
• Loxo Oncology
• ImmunityBio
• Monopar Therapeutics
• Chipscreen Biosciences, Ltd.
• Agenus
• C4 Therapeutics, Inc.
• Noxopharm Limited
• Moleculin Biotech, Inc.
• Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
• Tracon Pharmaceuticals Inc.
• Guangdong Xiangxue Precision Medical Technology Co., Ltd.
• Cornerstone Pharmaceuticals
• Takara Bio Inc.
• Jazz Pharmaceuticals
• Lyell Immunopharma
• Telix Pharmaceuticals

Key Products

• AL-3818
• Onfekafusp alfa
• Vigil
• Tazemetostat
• Aldoxorubicin
• TAS-116
• Selinexor
• NBTXR3
• APX005M
• GPX-150
• LTX-315
• Lenvatinib
• Chiauranib
• Zalifrelimab
• INCB081776
• LN-145-S1
• ABI-009
• Tivozanib
• LOXO-101
• sEphB4-HAS
• Sitravatinib
• Envafolimab
• Camrelizumab
• Tigilanol Tiglate
• Durvalumab
• Tremelimumab
• CFT8634
• NOX66
• Liposomal Annamycin
• 609A
• YH001
• TAEST16001
• CPI-613+Hydroxychloroquine
• TBI-1301
• Lurbinectedin
• LYL132

Show more